These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 16033822)

  • 21. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
    Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
    Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma.
    Shappell SB; Olson SJ; Hannah SE; Manning S; Roberts RL; Masumori N; Jisaka M; Boeglin WE; Vader V; Dave DS; Shook MF; Thomas TZ; Funk CD; Brash AR; Matusik RJ
    Cancer Res; 2003 May; 63(9):2256-67. PubMed ID: 12727848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis.
    Henrique R; Jerónimo C; Teixeira MR; Hoque MO; Carvalho AL; Pais I; Ribeiro FR; Oliveira J; Lopes C; Sidransky D
    Mol Cancer Res; 2006 Jan; 4(1):1-8. PubMed ID: 16446401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of human telomerase reverse transcriptase, Survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue.
    Bialkowska-Hobrzanska H; Driman DK; Fletcher R; Harry V; Razvi H
    Can J Urol; 2006 Feb; 13(1):2967-74. PubMed ID: 16515751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CCR2 expression correlates with prostate cancer progression.
    Lu Y; Cai Z; Xiao G; Liu Y; Keller ET; Yao Z; Zhang J
    J Cell Biochem; 2007 Jun; 101(3):676-85. PubMed ID: 17216598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activator protein 2alpha transcription factor expression is associated with luminal differentiation and is lost in prostate cancer.
    Ruiz M; Troncoso P; Bruns C; Bar-Eli M
    Clin Cancer Res; 2001 Dec; 7(12):4086-95. PubMed ID: 11751506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model.
    Diallo JS; Aldejmah A; Mouhim AF; Péant B; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
    Clin Cancer Res; 2007 Dec; 13(23):7044-52. PubMed ID: 18056181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
    Zhigang Z; Wenlu S
    Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.
    Kristiansen G; Pilarsky C; Wissmann C; Kaiser S; Bruemmendorf T; Roepcke S; Dahl E; Hinzmann B; Specht T; Pervan J; Stephan C; Loening S; Dietel M; Rosenthal A
    J Pathol; 2005 Feb; 205(3):359-76. PubMed ID: 15532095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of alpha-methylacyl-coA racemase among men with high grade prostatic intraepithelial neoplasia in prostate biopsies.
    Stewart J; Fleshner N; Cole H; Toi A; Sweet J
    J Urol; 2008 May; 179(5):1751-5; discussion 1755. PubMed ID: 18343427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
    Das S; Roth CP; Wasson LM; Vishwanatha JK
    Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
    Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
    Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canine prostate carcinomas express markers of urothelial and prostatic differentiation.
    LeRoy BE; Nadella MV; Toribio RE; Leav I; Rosol TJ
    Vet Pathol; 2004 Mar; 41(2):131-40. PubMed ID: 15017026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Quantitative detection of differential display code 3 mRNA in peripheral blood of patients with prostate cancer].
    Weng ZL; Yu KY; Mao XL; Tao ZH; Chen XD; Wu XL; Hu YP; Wang SQ; Li CD; Chen ZG
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(41):2911-5. PubMed ID: 17288789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer.
    Carvalho JR; Filipe L; Costa VL; Ribeiro FR; Martins AT; Teixeira MR; Jerónimo C; Henrique R
    Apoptosis; 2010 Aug; 15(8):956-65. PubMed ID: 20464497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins.
    Tsavaler L; Shapero MH; Morkowski S; Laus R
    Cancer Res; 2001 May; 61(9):3760-9. PubMed ID: 11325849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
    Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
    Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion.
    Bethel CR; Faith D; Li X; Guan B; Hicks JL; Lan F; Jenkins RB; Bieberich CJ; De Marzo AM
    Cancer Res; 2006 Nov; 66(22):10683-90. PubMed ID: 17108105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification and characterization of prostein, a novel prostate-specific protein.
    Xu J; Kalos M; Stolk JA; Zasloff EJ; Zhang X; Houghton RL; Filho AM; Nolasco M; Badaró R; Reed SG
    Cancer Res; 2001 Feb; 61(4):1563-8. PubMed ID: 11245466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.